---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-043944"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:39:34.190920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon posts Q2 net loss $7.4M; advances AT-1501 into kidney transplant, IgAN trials

## Summary
- Net loss $7.4M ($0.50/share) vs $2.6M loss in Q2 2020; R&D spend rose to $4.2M from $0.8M.
- Cash $101.1M as of June 30, 2021; company expects to fund operations into 2023.
- Health Canada cleared clinical trial of AT-1501 for kidney transplant rejection; initiation in Q4, data late 2022.
- FDA agreed on preclinical renal transplant study of AT-1501 monotherapy in 4 non-human primates; data mid-2022.
- Plans to develop AT-1501 for IgA nephropathy (IgAN), Phase 2 trial expected to start in Q4 2021.

## SEC filing metadata
- accession: 0001564590-21-043944
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/0001564590-21-043944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/eldn-8k_20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-043944
- JSON: https://secwatch.observer/filing/0001564590-21-043944.json
- Plain text: https://secwatch.observer/filing/0001564590-21-043944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.